Mutations in the von Hippel-Lindau (VHL) tumoursuppressor gene result in several forms of cancer. In the present study, we investigated the role of VHL subcellular localization in its antitumour properties. We generated renal cell carcinoma (RCC) lines stably expressing either exclusively nuclear (RCC/NLS-VHL), cytoplasmic (RCC/NES-VHL) or nucleo-cytoplasmic shuttling (RCC/DNES-VHL or RCC/VHL) forms of VHL and investigated several parameters linked to tumorigenesis and known to be dysregulated in VHL disease. Remarkably, although the expression of wild-type VHL is largely cytoplasmic, all of the antitumour properties of VHL tested could be reconstituted by expressing exclusively nuclear VHL.
Mutations in the von Hippel-Lindau (VHL) tumoursuppressor gene result in several forms of cancer. In the present study, we investigated the role of VHL subcellular localization in its antitumour properties. We generated renal cell carcinoma (RCC) lines stably expressing either exclusively nuclear (RCC/NLS-VHL), cytoplasmic (RCC/NES-VHL) or nucleo-cytoplasmic shuttling (RCC/DNES-VHL or RCC/VHL) forms of VHL and investigated several parameters linked to tumorigenesis and known to be dysregulated in VHL disease. Remarkably, although the expression of wild-type VHL is largely cytoplasmic, all of the antitumour properties of VHL tested could be reconstituted by expressing exclusively nuclear VHL. Oncogene (2003 Oncogene ( ) 22, 3992-3997. doi:10.1038 Keywords: VHL; HIF-1a; RCC Von Hippel-Lindau (VHL) disease is characterized by tumours of the kidney (renal cell carcinoma, RCC), CNS, eye and pancreas. Mutations in the VHL gene have been divided into those that are characteristically grouped with tumour types; however, most, if not all, impair the ability of the VHL protein to function as an E3 ubiquitin ligase (see , for a review). The VHL protein was originally associated with the repression of transcription elongation, via its interaction with the elongin B/C heterodimer (Duan et al., 1995) . Subsequent studies on VHL revealed a broader spectrum of effect, including restoration of an extracellular matrix (Ohh et al., 1998) , cellular differentiation (Davidowitz et al., 2001) , cell cycle effects (Pause et al., 1998) and attenuation of RCC cell invasiveness (Koochekpour et al., 1999) . Recent research has also revealed VHL to constitute part of a larger complex that collectively ubiquitinates target proteins such as hypoxia-inducible factor-1a (HIF-1a) and HIF-like factor (HLF), via a hydroxylated proline Jaakkola et al., 2001) . The dysregulated expression of these factors is thought to contribute to the vascularization of tumours associated with VHL disease, since HIF-1a and HLF stimulate the transcription of several genes involved in angiogenesis (see Clifford and Maher, 2000 , for a review). One of the difficulties in separating many of the discrete cellular roles of VHL is that individual mutations in the gene result in widespread changes to the protein's function. Thus, a mutation that affects HIF-1a binding may also impair several other biological pathways controlled or modulated by VHL. To this end, we have expressed wild-type VHL in different cell compartments to observe whether some of VHL's antitumour properties can be separated from others. We present data that suggest many features of VHL's tumour-suppressor activities are contingent upon its exclusively nuclear localization and are independent of cytoplasmic access or HIF-1a/ HLF regulation.
Previous studies have revealed that VHL is predominantly cytoplasmic (Lee et al., 1996) , but that the protein shuttles between nucleus and cytoplasm, a phenomenon that can be altered either by cell density (Lee et al., 1996) or by transcriptional arrest (Lee et al., 1999) . In general, VHL is predominantly nuclear at low cell density and cytoplasmic at high (Lee et al., 1996) , and upon transcriptional arrest VHL accumulates in the nucleus (Lee et al., 1999) . The biological significance of this is unclear; however, it has been postulated (Lee et al., 1999; Bonicalzi et al., 2001 ) that nucleocytoplasmic shuttling of VHL may somehow be important for its antitumour effects, since the same exon (exon 2) that controls shuttling is also a b-domainbinding surface for the VHL E3 ligase. In the present study, we generated N-terminal haemagglutin-tagged fusions of VHL to various nuclear import (NLS) and export (NES) sequences (Figure 1a) , and investigated their subcellular distribution when fused to C-terminal enhanced yellow fluorescent protein (EYFP, Figure 1b) . Consistent with reports from other labs, both wild-type VHL-EYFP and DNES-VHL-EYFP exhibited predominantly cytoplasmic distribution that showed nuclear accumulation when treated with the transcriptional inhibitors actinomycin D and DRB. Conversely, NES-VHL-EYFP and NLS-VHL-EYFP failed to show any changes in cellular distribution following treatment with transcriptional inhibitors and were exclusively cytoplasmic (NES-VHL-EYFP) or nuclear (NLS-VHL-EYFP). The former of these findings is consistent with a prior study (Lee et al., 1999) , and suggests that VHL shuttling can be overriden by the addition of strong import or export signals. In addition, when the VHL constructs were transfected into 293 T cells without the EYFP tag, distribution remained exclusively nuclear (NLS-VHL, VHL-NLS), cytoplasmic (NES-VHL), or both (VHL, DNES-VHL) even at high transient expression levels. Moreover, subfractionation of 786-0 cells stably transfected with NES-VHL exhibited cytoplasmic distribution only, with the other VHL forms showing both nuclear and cytoplasmic distribution. In the case of NLS-VHL, we interpret this to reflect the previously reported (Lee et al., 1996) unavoidable leakage of some nuclear VHL out of the nucleus upon sample preparation.
Having established the subcellular compartmentalization of these constructs, we next stably transfected them into RCC cells without the C-terminal EYFP, in an effort to study the function of VHL with minimal structural alteration. Firstly, these recombinant VHL/ RCC lines were tested for their ability to exhibit downregulation of HIF-1a and associated HREmediated transcription (Figure 2 ). In all cases, the localization of VHL, in either 786-0 or RCC4 cells, appeared to have little effect on the regulation on either HIF-1a or glucose transporter 1 (GLUT1) expression. The ubiquitination of HIF-1a, and by inference HLF, is thus proposed to be carried efficiently by either cytoplasmic, nuclear or shuttling forms of the VHL E3 ligase. Indeed, HIF-1a has been demonstrated to be degraded in either nucleus or cytoplasm (Berra et al., 2001) , although these studies were performed in cell lines in which VHL has access to both cell compartments. Our data disagree with a previous study in which VHL fused to a C-terminal GFP-NES signal was shown to be ineffective in downregulating GLUT1 expression (Lee et al., 1999) . To what extent large C-terminal extensions to VHL influence its activity is unclear; however, we have observed in a separate study (Lewis MD and Roberts BJ, submitted for publication) that the Cterminal a-helical domain of VHL is an important determinant in its effective ubiquitination of HIF-1a. We also consider the possibility that prolyl hydroxylase domain containing proteins (PHD) PHD2 and PHD3, which are largely cytoplasmic (Huang et al., 2002) and regulated by hypoxia (Epstein et al., 2001) , may dictate lower rates of cytoplasmic VHL/HIF-1a capture than constitutive nuclear PHD1 (Huang et al., 2002) . Overall, however, our data suggest that both nuclear and cytoplasmic forms of the VHL E3 ligase are capable of ubiquitinating and degrading HIF-1a under normal cell growth conditions. Moreover, these functions exhibit no special requirement for VHL nucleo-cytoplasmic shuttling. Our data are consistent with two previous reports suggesting HIF-1a can be degraded in either nucleus or cytoplasm (Berra et al., 2001) or nucleus only (Tanimoto et al., 2000) , but is inconsistent with a recent report (Groulx and Lee, 2002) suggesting that degradation of HIF-1a requires nucleo-cytoplasmic shuttling. Importantly, the authors of the latter paper point out that their studies do not preclude cytoplasmic HIF-1a degradation by VHL. Thus, we see no reason why, as observed in the present study, HIF-1a degradation cannot be achieved by either nuclear or cytoplasmic forms of the VHL E3 ligase. Moreover, in the aforementioned study, HIF-1a is still rapidly ubiquitinated and degraded in the nucleus with a nuclear accumulated form of VHL.
We next investigated several other properties of VHL associated with its antitumour effects. The first of these was VHL's ability to restore fibronectin deposition, since the impaired formation of an extracellular matrix is frequently observed in tumour cell lines. In RCC cells expressing either nuclear, cytoplasmic or shuttling forms of VHL (Figure 3 ), only nuclear and shuttling forms of VHL showed appreciable fibronectin deposition in RCC4 cells after 24 h (Figure 3a) . In contrast, RCC4 cells alone were largely deficient in depositing insoluble fibronectin, with minimal fibronectin staining observed in NES-VHL/RCC4 cells. We then tested the ability of cytoplasmic (NES-VHL) and shuttling (DNES-VHL) to bind intracellular fibronectin and observed no difference (Figure 3b ). A C-terminal truncation of VHL, pre- NES-VHL, DNES-VHL and NLS-VHL described in (a), were fused at the C-terminus in-frame to EYFP and transfected into 293T cells. At 24 h following transfection, cells were fixed in 2% formaldehyde/PBS and visualized using fluorescence microscopy. In the case of cells transfected with VHL, NES-VHL or DNES-VHL, duplicate dishes were treated with actinomycin-D/DRB. A further 4 h following chemical treatment, cells were compared directly with untreated controls to assess nuclear accumulation of VHL. RCC4 cells were the gift of Professor CHCM Buys, Department of Medical Genetics, University of Groningen, Groningen, the Netherlands. 786-0 cells were obtained from ATCC. All cell lines used in this study were maintained in DMEM/10% FCS (Invitrogen), at 5% CO 2 , 21% O 2 , 371C. Monoclonal stable cell lines were generated as previously described (Lewis MD and Roberts BJ, submitted for publication). The VHL cDNA used in these studies was generously provided as an N-terminal HA fusion construct in the pRCCV vector by Dr WG Kaelin, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. The N-terminal fusion NLS-VHL containing tandem large T-antigen monopartite NLS sequences was generated firstly using 5 0 -GGTCTAGAACCATGGCGCCAAAGAAGAA-GAGGAAGGTGTACCCGTACGACGTCCCAGACTACGCGCCC-CGGAGGGCGGAG-3 0 and 5 0 GTCTTTCTGCACATT-TGGGTG-3 0 , then subcloning the XbaI/BglII fragment into VHL/EF-IRES-puro using NheI/BglII. This construct was then used as the template for PCR with the following primers: 5 0 -GGCTCTAGAACCATGCCGCCCAAAAAAAAACGGAAAGTCGCGCC-AAAGAAGAA-GAGGAAGGTG-3 0 and 5 0 -GTCTTTCTGC-ACATTTGGGTG-3 0 . The XbaI/BglII fragment containing the tandem NLS sequences was then subcloned into the parent VHL/EF-IRES-puro using NheI/BglII to generate NLS-VHL/EF-IRES-puro. NES-VHL/EF-IRES-puro and VHL-NLS/EF-IRES-puro were generated as described elsewhere (Roberts BJ, submitted for publication). The NES-VHL cDNA was used as the template for the generation of DNES-VHL/EF-IRES-puro using the primers: 5 0 -GGTCTAGAACCATGGAGTTGCCGC-CGCGGGAGAGGCTGACGCTGTACCCGTACGACGTCCCAGACTACGCGCC-CCGGAGG-3 0 and 5 0 -GTCTTTCTGCACATTTG-GGTG-3 0 . The XbaI/BglII fragment was subcloned into VHL/EF-IRES-puro vector using NheI/BglII. The sequence of EYFP was amplified from a vector containing EYFP (pTr5 mDRc IRES EYFP from the laboratory of Dr ML Whitelaw, School of Molecular Life Sciences, University of Adelaide). The primer used to amplify the cDNA encoding EYFP were as follows: 5 0 -TGAATTCATGGTGAGCAAGGGCGAGGAGC-3 0 and 5 0 -GCTCTAGATTACTT-GTA-CAGCTCTGTCCA-3 0 . In the second step, the 3 0 end of VHL-EF-IRES-puro was amplified using the following primers: 5 0 -GAATTATTTGTGCCAGCTCTCAATGTTGACGGA-3 0 and 5 0 -CGAATTCTCGAGCGCAATCTCCC-ATCCGTTG-3 0 . The resulting fragment was cut with EcoRI and BglII and subcloned into VHL-EF-IRES-puro using BglII/EcoRI. The EYFP cDNA was then excised from EYFP/Gem-T using EcoRI/XbaI and subcloned into VHL/EF-IRES-puro digested with EcoRI/XbaI. The resulting construct, verified by sequencing, was designated VHL-EYFP/EF/IRES/puro. To subclone the C-terminal EYFP fusion onto other VHL constructs VHL-EYFP/EF-IRES-puro was cut with BglII/KpnI and ligated into the correponding sites on other VHL vectors. For fluorescence, VHL-EYFP fusions were transfected (1 mg into 60% confluent 293T cells) and fixed 24 h following transfection, or, treated with actinomycin D (1 mg/ml) or DRB (25 mg/ml, both dissolved in a DMSO stock) for a further 4 h prior to fixation in 2% formaldehyde/PBS for 15 min. Cells were visualized and photographed using an Olympus model CX-40 microscope fitted with fluoresence capabilities and a DP11 digital camera. For the immunofluorescence analysis of VHL shown in (c), 293 T cells were transfected with appropriate HA-tagged VHL construct and 20 h later cells washed with PBS and fixed for 15 min with a solution containing 2% formaldehyde/PBS. Cells were then washed with PBS and blocked with 5% milk/PBS for 30 min. Cells were incubated with 12CA5/10%FCS/0.3 % Tween-20 for 3 h, washed twice with PBS, and incubated with anti-mouse IgG (Dako) coupled to FITC for 1 h. Following a final wash with PBS, cells were visualized and photographed using a broad-pass green filter on a Nikon TE-200 microscope fitted with fluorescence capabilities. (d) Nuclear and cytoplasmic cell extracts were obtained using a previously described method (Roberts and Whitelaw, 1999) from 786-0 cells stably expressing various forms of VHL as shown in the figure. Equal nuclear and cytoplasmic protein samples were determined using the Pierce protein determination kit (Pierce Chemicals) and subjected to immunoblotting using 12CA5 IgG (anti-HA) viously shown to exhibit impaired fibronectin binding (Ohh et al., 1998) , was deficient in this respect, suggesting that fibronectin binding is a property of full-length VHL. We therefore conclude that the ability of VHL to restore the deposition of extracellular fibronectin in RCC cells is primarily a product of its nuclear localization. The next parameter investigated was the ability of VHL to restore downregulation of integrin a 5 expression upon prolonged cell contact. In 786-0 cells, integrin a 5 expression remains elevated following prolonged cell contact (Davidowitz et al., 2001 , and the present study), indicative of tumour cells and consistent with the view that tumorigenesis involves aberrant extracellular matrix remodelling and elevated integrin expression (see Ruoslahti, 1999 , for a review).
Investigation of VHL localization within this context revealed that only shuttling and nuclear forms of VHL restore integrin a 5 downregulation, with cytoplasmic VHL exhibiting integrin a 5 expression, essentially the same as the parent 786-0 cell line (Figure 3c ). These findings suggest that integrin downregulation, and extracellular matrix remodelling in general, is controlled by the nuclear localization of VHL. We compared these observations against the morphology of RCC4 cells expressing the various recombinant forms of VHL (Figure 3d ) and noted that only cells possessing nuclear or shuttling forms of VHL formed the epithelial sheet alluded to by other researchers (Davidowitz et al., 2001) . In contrast, RCC4 and NES-VHL/RCC4 cells grow haphazardly on the monolayer and fail to form an epithelial sheet. These data suggest that differentiation of RCC cells is also controlled by the nuclear localization of VHL, and is independent of its shuttling or cytoplasmic properties.
Finally, we tested recombinant RCC VHL cell lines in a matrigel assay, since VHL has previously been demonstrated to significantly inhibit RCC cell invasion using this technique (Koochekpour et al., 1999) . Data from these experiments revealed that the exclusively nuclear expression of VHL in 786-0 cells dramatically reduced the invasiveness of 786-0 cells. In contrast, cells expressing cytoplasmic VHL were significantly less able than nuclear VHL to reduce the invasiveness of 786-0 cells. Cells expressing the shuttling form of VHL showed invasiveness in between that of nuclear and cytoplasmic forms, suggesting that exclusively nuclear VHL localization may be more effective than shuttling VHL in reducing tumour cell invasion.
It is becoming increasingly apparent that VHL possesses multiple tumour-suppressor functions. Some Figure 2 Role of subcellular distribution of VHL in the degradation of HIF-1a and GLUT1 expression. (a) RCC4 cells were stably transfected with either full-length VHL, or VHL Nterminal fusions containing either N-terminal NES, DNES or NLS motifs. Cells expressing the various recombinant forms of VHL were then lysed using whole-cell extract (WCE) buffer, protein content determined, and 100 mg of sample loaded and run on 6% (HIF-1a) or 10% (VHL, 12CA5) SDS-PAGE gels. Gels were transferred to nitrocellulose, and probed with monoclonal antibodies to either HIF-1a or VHL. HIF-1a migrated at an approximate M r of 130 kDa throughout these experiments, HAtagged VHL and variants thereof at an approximate M r of 28-40 kDa. (b) The effects of VHL distribution on GLUT1 protein expression in 786-0 and RCC4 cells were determined following stable transfection of recombinant VHL. Cells were lysed using WCE buffer, protein concentrations determined, and equal quantities of protein extract added to a saturated urea solution at a 3 : 1 v/v ratio prior to mixing and addition of SDS-PAGE sample buffer. Unboiled samples were then loaded onto 10% SDS-PAGE gels, subjected to electrophoresis, transferred to nitrocellulose, and immunoblotted with a monoclonal anti-GLUT1 IgG (Alpha Diagnostic). (c) VHL fused via its C-terminus to the bipartite nuclear localization signal described in Figure 1 (a) was stably transfected into RCC4 cells and its effects on HIF-1a and GLUT1 expression determined essentially as described in (a) and (b). In each lane, equal protein samples were loaded, electrophoresed, transferred to nitrocellulose and probed with the appropriate antibodies Figure 3 Various effects of VHL subcellular distribution on parameters associated with VHL's tumour-suppressor activity. (a) RCC4 cells, or those stably transfected with VHL, or the constructs denoted in the figure, were cultured, trypsinized, and plated on 35 mm dishes. At 24 h following plating cells were harvested in duplicate dishes by cell scraping and insoluble fibronectin deposition determined. Samples extracted were denatured in SDS-PAGE sample buffer and run on 6% SDS-PAGE gels prior to transfer to nitrocellulose filters and immunoblotting with antifibronectin IgG. (b) RCC4 cells or VHL stable transfectants were lysed in WCE buffer and VHL immunoprecipitated using anti-VHL (12CA5). Denatured precipitated samples were then split and run on either 6% (fibronectin) or 10% (12CA5) SDS-PAGE gels, prior to transfer to nitrocellulose and immunoblotting with either fibronectin or 12CA5 IgG. Intracellular fibronectin migrated at an approximate M r of 200-240 kDa. (c) 786-0 alone or cells stably transfected with either VHL, NES-VHL, DNES-VHL, NLS-VHL or VHL-NLS were plated at high cell confluence and allowed to grow for up to 6 days. On each day, cells were harvested in WCE buffer, protein concentration determined, and equal quantities of each sample run on 6% SDS-PAGE gels, transferred to nitrocellulose, and blotted with monoclonal antisera specific to the integrin a 5 subunit. Data obtained at days 5 and 6 were representative of integrin a 5 expression up to 10 days following cell plating (data not shown). (d) RCC4 cells, or those stably transfected with either NLS-VHL, DNES-VHL, or NES-VHL, were plated at approximately 80% confluence and allowed to grow on 35 mm dishes for 48 h. Cells were visualized and photographed using conventional light microscopy. (e) Equal numbers of 786-0 cells stably transfected with either NLS-VHL, NES-VHL or DNES-VHL were plated on matrigel and their invasion through the matrix determined over a 16 h period. The number of cells passing through the matrigel layer over this period is denoted on the y-axis and is the mean7s.d. of triplicate determinations. Methods involving fibronectin deposition, intracellular fibronectin binding, integrin a 5 measurement, immunoblotting, immunoprecipitation and matrigel tumour invasion have all been described in another manuscript (Lewis MD and Roberts BJ, submitted for publication) undoubtedly involve repression of tumour vascularization; other markers, such as those investigated in the present study, are clearly products of VHL's nuclear distribution and do not require cytoplasmic access. Obvious candidate pathways for nuclear VHL regulation include the cell cycle and/or transcriptional repression. How important deregulated HIF-1a/HLF expression is in VHL disease is at present unclear, since there are mutations in VHL that do not appear to affect this pathway (Clifford et al., 2001; Hoffman et al., 2001) . Furthermore, a recent report has shown that mice constitutively overexpressing HIF-1a do not exhibit any signs of tumorigenesis (Elson et al., 2001) . For these reasons, detailed investigation of VHL's role in the nucleus should provide valuable insights into the factors underpinning VHL disease.
